Volume | 53,979 |
|
|||||
News | - | ||||||
Day High | 3.62 | Low High |
|||||
Day Low | 3.4736 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Galectin Therapeutics Inc | GALT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.55 | 3.4736 | 3.62 | 3.51 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
458 | 53,979 | $ 3.56 | $ 192,186 | - | 1.28 - 4.2684 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
12:43:22 | 200 | $ 3.56 | USD |
Galectin Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
220.18M | 61.85M | - | 0 | -44.81M | -0.72 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Galectin Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GALT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.36 | 3.78 | 3.20 | 3.48 | 181,767 | 0.20 | 5.95% |
1 Month | 2.46 | 4.2684 | 2.46 | 3.59 | 322,375 | 1.10 | 44.72% |
3 Months | 1.70 | 4.2684 | 1.59 | 3.09 | 167,320 | 1.86 | 109.41% |
6 Months | 2.03 | 4.2684 | 1.555 | 2.70 | 111,747 | 1.53 | 75.37% |
1 Year | 1.77 | 4.2684 | 1.28 | 2.36 | 83,092 | 1.79 | 101.13% |
3 Years | 4.43 | 4.57 | 1.02 | 3.11 | 304,383 | -0.87 | -19.64% |
5 Years | 4.25 | 5.70 | 1.02 | 3.02 | 398,588 | -0.69 | -16.24% |
Galectin Therapeutics Description
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its lead galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis. |